Elsevier

Clinical Therapeutics

Volume 28, Issue 4, April 2006, Pages 591-599
Clinical Therapeutics

Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: An analysis of patient data from a Maryland-based health maintenance organization

https://doi.org/10.1016/j.clinthera.2006.04.012Get rights and content

Abstract

Background:

Coronary heart disease (CHD) is the leading cause of death in men and women in the United States, with a higher mortality in women, despite a lower prevalence. Statins effectively treat dyslipidemia and reduce the risk of CHD mortality.

Objective:

The objective of this study was to evaluate the treatment of dyslipidemia in patients with CHD and determine if sex differences exist.

Methods:

This was a retrospective chart review performed within a multioffice staff model health maintenance organization of ∼70,000 members. An administrative database, containing inpatient and out-patient medical claims, was used to identify patients with CHD based on diagnostic codes. Charts were randomly selected and the following information was obtained from chart review: age; sex; risk factors for CHD; diagnosis and/or prescription for depression; blood low-density lipoprotein cholesterol (LDL-C) level; and drug, dosage, and duration of prescribed lipid-lowering therapy. Exclusion criteria included missing charts and unavailable LDL-C values. LDL-C values were classified as at target if LDL-C <2.59 mmol/L (<100 mg/dL). Patients receiving statin monotherapy were categorized into 3 potency groups, based on efficacy to lower LDL-C values: high (atorvastatin 20–80 mg, lovastatin 80 mg), medium (atorvastatin 10 mg, pravastatin 40 mg, simvastatin 200 mg), and low (fluvastatin 10–40 mg, lovastatin 10–40 mg, pravastatin 10–20 mg, simvastatin 5–10 mg).

Results:

A total of 1487 adult patients (64.4% male with a mean (SD) age of 65.7 (11.8) years were identified, based on diagnostic codes for CHD. Three hundred twenty charts were selected for review. After exclusion, the final study cohort was 290 patients. The cohort was 66.2% male (192/290) with no significant difference in mean (SD) age between men (65.2 [9.2] years) and women (66.9 [10.5] years). Weight of women ranged from 85 to 305 lbs; 134 to 288 lbs for men. Among the study cohort, 46.2% (134/290) of the patients achieved the target LDL-C of <2.59 mmol/L (<100 mg/dL), with significantly more men (51.0% [98/192]) than women (36.7% [36/98]) reaching target (P = 0.021). Lipid-lowering therapy was prescribed to 68.6% (199/290) of the patients, with no significant sex differences (men, 71.4% [137/192]; women, 63.3% [62/98]). Of the patients prescribed lipid-lowering therapy (primarily statins), 53.8% (107/199) achieved target LDL-C. There was no significant sex difference in the potency groups prescribed, and the rate of LDL-C target attainment was similar across potency groups. Overall, 70.3% of patients who did not receive lipid-lowering therapy had inadequately controlled LDL-C (women, 31/36 [86.1 %]; men, 33/55 [60.0%] [P = 0.008]).

Conclusions:

The majority of CHD patients from a Maryland-based health maintenance organization had elevated LDL-C values, despite a lipid-lowering prescription rate of 68.6%. A significant gap in dyslipidemia treatment in these CHD patients remained, particularly for women.

References (38)

  • MaynardC. et al.

    Gender differences in the treatment and outcome of acute myocardial infarction. Results from the Myocardial Infarction Triage and Intervention Registry

    Arch Intern Med

    (1992)
  • ClarkeK.W. et al.

    Do women with acute myocardial infarction receive the same treatment as men?

    BMJ

    (1994)
  • GregorR.D. et al.

    Gender differences in the presentation, treatment, and short-term mortality of acute chest pain

    Clin Invest Med

    (1994)
  • VaccarinoV. et al.

    Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants

    N Engl J Med

    (1999)
  • BursteinJ.M. et al.

    Management of congestive heart failure: A gender gap may still exist. Observations from a contemporary cohort

    BMC Cardiovasc Disord

    (2003)
  • Di CeccoR. et al.

    Is there a clinically significant gender bias in post-myocardial infarction pharmacological management in the older (>60) population of a primary care practice?

    BMC Fam Pract

    (2002)
  • Hippisley-CoxJ. et al.

    Sex inequalities in ischaemic heart disease in general practice: Cross-sectional survey

    BMJ

    (2001)
  • GrundyS.M. et al.

    Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

    Circulation

    (2004)
  • LaRosaJ.C. et al.

    Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials

    JAMA

    (1999)
  • Cited by (25)

    • The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland

      2018, Atherosclerosis
      Citation Excerpt :

      Then, the FH prevalence was calculated as weighted mean, 3.3%. The probability of hLDL in non-FH, ACS patients is increased; we assumed 87.14% (based on the probability of hLDL in ACS patients [40]). The risk of falsely attributing hLDL to other-than-FH causes in (undiagnosed) truly FH patients was estimated to 20% (experts' opinion).

    • Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States

      2016, Journal of Clinical Lipidology
      Citation Excerpt :

      Patients with established CHD and CHD risk equivalent (CHD RE) indications have a high risk of subsequent CV events including myocardial infarction (MI), stroke, and death, and statins have been recommended as the first choice of treatment in these patients to reduce CVD events.9 However, statins also have their challenges with several studies indicating suboptimal use in high-risk patients,10–14 elevated LDL-C levels in spite of statin use,15 and the issue of residual CVD risk in patients even with high-intensity statin treatment.16–19 The National Cholesterol Education Program Adult Treatment Panel III (ATP III) guidelines considered patients with CHD or a CHD RE diagnosis to be high-risk patients and recommended an LDL-C goal of <100 mg/dL.20

    • Gender difference in statin intervention on blood lipid control among patients with coronary heart disease

      2013, International Journal of Gerontology
      Citation Excerpt :

      In the Maryland-based health maintenance organization study, there was no difference between the proportion of men (71.4%) and women (63.3%) prescribed lipid-lowering therapy. As a result, more men (51.0%) than women (36.7%) reached the LDL-C of <2.59 mmol/L (<100 mg/dL)18. A report from China showed that in patients with high cardiovascular risk, the rate of statin therapy was much higher (82.2%); however, the LDL-C attainment (<2.6 mmol/L, 100 mg/dL) rate was relatively lower in men (45.5%) and women (28.5%)15.

    • Hyperlipidemia in patients with schizophrenia: A national population-based study

      2012, General Hospital Psychiatry
      Citation Excerpt :

      Of interest, the incidence rate of hyperlipidemia for women is much greater that of men after age of 50 years, which was in accordance with other surveys about metabolic problems [6,27]. Hormones, such as estrogen, protect women from the development of risk factors for CHD not only in the general population [32,33] but also in schizophrenic patients [8,13]. After menopause, the hyperprolactinemia status and change of gonadal hormone levels are much more obvious for women and make them vulnerable to having poor lipid profiles [34].

    View all citing articles on Scopus
    View full text